FDA grants fast track designation for diffuse intrinsic pontine glioma treatment
The U.S. Food and Drug Administration has granted fast track designation for OKN-007 (Oblato, Inc) for diffuse intrinsic pontine glioma (DIPG), according to a press release.
DIPG is a rare pediatric brainstem cancer with a 5-year survival of less than 1%.
“We anticipate that the fast track designation for DIPG will shorten the NDA review process. The [Oblato] will make every effort to develop this treatment for this rare pediatric disease,” said an official from Oblato in the press release.
Read the full press release here.